Search bioRxiv⌕ Search

Biology subjects

Lardinois, D.

Publications and source records attributed to Lardinois, D..

2 recordsLinked to original sources

Multimodal single-cell profiling of T cell specificity and reactivity in lung cancer

Adoptive transfer of autologous tumor-infiltrating lymphocyte T cells (TILs) offers one of the most promising approaches for cancer immunotherapy. However, high variability in patient responses highlight the need for an enhanced understanding of the transcriptional phenotypes of TILs and reactivity of their T cell receptors (TCR). Here, we employ single-cell multiomics approaches and TCR functional screening to investigate TILs from treatment-naive non-small cell lung cancer patients. This comprehensive analysis integrates scRNA-seq, scTCR-seq, and scATAC-seq, enabling a high-resolution examination of TILs within lung cancer tissue, as well as the adjacent non-tumor tissue. We apply a cellular functional screening platform to identify reactive TCRs that represent >1,000 TILs and have specificity towards a multitude of targets, including primary tumor cells, neoantigens, tumor-associated antigens, and viral antigens. Tumor-reactive TILs were primarily associated with dysfunctional phenotypes, whereas viral antigen-reactive TCRs were found in effector phenotype clusters. Key marker genes were identified and used to construct a tumor or viral reactivity score. Comparing clones shared in tumor and non-tumor tissue, a higher fraction of exhausted cells was observed in the tumor tissue, whereas non-tumor adjacent tissue possessed more effector cells, thus providing insight into potential sources for therapeutic T cells. Elucidating the specific T cell populations within TILs and their associated TCRs may support strategies to enhance the efficacy of TIL-based therapies. Graphical AbstractO_ST_ABSMultimodal single cell profiling and reactivity testing of TILsC_ST_ABS(A) CD8+ T cells of treatment naive non-small cell lung cancer patients and adjacent lung tissue were isolated by fluorescence-activated cell sorting (FACS) and were then subjected to scRNA-seq + scTCR-seq or scATAC-seq. (B) TCRs were functionally screened using a cellular platform (TnT cells) and target cells (tumor cells, antigen-pulsed antigen-presenting cells, PBMCs) by flow cytometry and deep sequencing. (C) scRNA-seq + scATAC-seq allowed trajectory inference of transcription factors and genes along pseudotime. (D) Gene scores for tumor- and virus-reactivity were developed by combining functional reactivity and transcriptomic profiling for each CD8+ T cell. (E) TIL scRNA-seq pre and post IL-2 treatment in tumor suspension displayed as alluvial plot shows change of clonal cell state composition. O_FIG O_LINKSMALLFIG WIDTH=196 HEIGHT=200 SRC="FIGDIR/small/560863v1_ufig1.gif" ALT="Figure 1"> View larger version (51K): org.highwire.dtl.DTLVardef@12fcc20org.highwire.dtl.DTLVardef@1027dccorg.highwire.dtl.DTLVardef@911711org.highwire.dtl.DTLVardef@18171e5_HPS_FORMAT_FIGEXP M_FIG C_FIG

immunology↗

Engagement of sialylated glycans with Siglec receptors on myeloid suppressor cells inhibit anti-cancer immunity via CCL2

Overexpression of sialic acids on glycans, called hypersialylation is a common alteration found in cancer. Hypersialylation can, for example, enhance immune evasion via interaction with sialic acid-binding immunoglobulin-like lectin (Siglec) receptors on tumor-infiltrating immune cells. Here, we tested the role of sialic acid on myeloid-derived suppressor cells (MDSCs) and their interaction with Siglec receptors. We found that MDSCs derived from the blood of lung cancer patients and tumor-bearing mice strongly express inhibitory Siglec receptors. In murine cancer models of emergency myelopoiesis, Siglec-E knockout on myeloid cells resulted in prolonged survival and increased infiltration of activated T cells. Targeting suppressive myeloid cells by blocking Siglec receptors or desialylation led to strong reduction of their suppressive potential. We further identified CCL2 as mediator involved in T cell suppression upon interaction of sialoglycans and Siglec receptors on MDSCs. Our results provide mechanistic insights how sialylated glycans inhibit anti-cancer immunity by facilitating CCL2 expression. O_FIG O_LINKSMALLFIG WIDTH=142 HEIGHT=200 SRC="FIGDIR/small/547025v1_ufig1.gif" ALT="Figure 1"> View larger version (42K): org.highwire.dtl.DTLVardef@e7664forg.highwire.dtl.DTLVardef@1edd220org.highwire.dtl.DTLVardef@7e630dorg.highwire.dtl.DTLVardef@198ff40_HPS_FORMAT_FIGEXP M_FIG C_FIG

immunology↗